## UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549

### FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 8, 2024



#### Ascent Industries Co.

Delaware

(Exact name of registrant as specified in its charter) **0-19687** 

57-0426694

(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification No.)
1400 16th Street, Suite 270,		
Oak Brook, Illinois	<del></del>	60523
(Address of principal executive offices)	(630) 884-9181	(Zip Code)
	(Registrant's telephone number, including area code)	
	Inapplicable	
(East	mer name or former address if changed since last	
,	č	1 /
Check the appropriate box below if the Form 8-K filing is inter General Instruction A.2. below):	nded to simultaneously satisfy the filing obligatio	n of the registrant under any of the following provisions (see
<ul> <li>□ Written communications pursuant to Rule 425 under the S</li> <li>□ Soliciting material pursuant to Rule 14a-12 under the Exc</li> <li>□ Pre-commencement communications pursuant to Rule 14a</li> <li>□ Pre-commencement communications pursuant to Rule 13a</li> </ul>	hange Act (17 CFR 240.14a-12) d-2(b) under the Exchange Act (17 CFR 240.14d-	\ //
Sec	curities registered pursuant to Section 12(b) of the	e Act:
Title of each class	Trading Symbol	Name of exchange on which registered
Common Stock, par value \$1.00 per share	ACNT	NASDAQ Global Market
12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.1 Emerging growth company □	2b-2 of this chapter).  e registrant has elected not to use the extended tr	curities Act of 1933 (17 CFR §230.405 of this chapter) or Rule ansition period for complying with any new or revised financial

#### Item 2.02. Results of Operations and Financial Condition

On May 8, 2024, Ascent Industries Co. ("the Company") issued a press release announcing financial information for its first quarter ended March 31, 2024. The press release is attached as Exhibit 99.1 to this Form 8-K and is furnished to, but not filed with, the Commission.

## Item 9.01. Financial Statements and Exhibits

(d) Exhibits

<u>Exhibit Number</u> <u>Description of Exhibit</u>

99.1 Ascent Industries Co. Press Release dated May 8, 2024

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

## SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on behalf by the undersigned hereunto duly authorized.

Ascent Industries Co.

Dated: May 8, 2024 By: /s/ Ryan Kavalauskas

Ryan Kavalauskas Chief Financial Officer



## **Ascent Industries Reports First Quarter 2024 Results**

Oak Brook, Illinois, May 8, 2024 – Ascent Industries Co. (Nasdaq: ACNT) ("Ascent" or the "Company"), an industrials company focused on the production of specialty chemicals and industrial tubular products, is reporting its results for the first quarter ended March 31, 2024.

#### First Quarter 2024 Summary<sup>1</sup>

(in millions, except per share and margin)	Q1 2024	Q1 2023	Change
Net Sales	\$44.1	\$54.9	(19.6)%
Gross Profit	\$2.5	\$1.5	72.4%
Gross Profit Margin	5.7%	2.7%	300bps
Net (Loss)	\$(4.7)	\$(5.8)	18.6%
Diluted (Loss) per Share	\$(0.47)	\$(0.57)	17.5%
Adjusted EBITDA	\$(3.1)	\$(3.7)	16.6%
Adjusted EBITDA Margin	(7.1)%	(6.8)%	(30)bps

<sup>&</sup>lt;sup>1</sup>On June 2, 2023, the Board of Directors of Ascent made the decision to permanently cease operations at the Company's welded pipe and tube facility located in Munhall, PA ("Munhall") effective on August 31, 2023. On December 22, 2023, the Company closed on a transaction to sell substantially all of the assets of Specialty Pipe & Tube ("SPT"). As a result, financial results from Munhall & SPT have been categorized into discontinued operations.

#### **Management Commentary**

"The first quarter of 2024 marked a period of structural cost reduction and stabilization efforts across the enterprise," said Ascent CEO Bryan Kitchen. "Without question, our initial efforts to optimize both cash and costs have helped drive year-over-year improvements across our consolidated gross margin and bottom line, while operating within the confines of our own free cash flow. Aggressive self-help has been at the core of our ability to overcome ongoing market headwinds that have resulted in a year-over-year decline in total net sales."

"As promised, in just a short period of time we have made progress in laying the groundwork for driving profitable growth through the optimization of our product mix while recapitalizing our SG&A across both segments. These actions, coupled with a continued focus on driving efficiencies across all sites and functions, will create a more predictable, reliable, and profitable operating model moving forward. Momentum is building, and we expect continued improvements in our financial results throughout 2024. We are on the right track to create durable value for shareholders."

#### First Quarter 2024 Financial Results

Net sales from continuing operations were \$44.1 million compared to \$54.9 million in the first quarter of 2023, primarily attributable to decreased end-market demand and destocking trends across both segments.

Gross profit from continuing operations improved to \$2.5 million, or 5.7% of net sales, compared to \$1.5 million, or 2.7% of net sales, in the first quarter of 2023. The increase was primarily attributable to improved strategic sourcing initiatives and cost improvements.

Net loss from continuing operations decreased to \$4.7 million, or \$(0.47) diluted loss per share, compared to net loss from continuing operations of \$5.8 million, or \$(0.57) diluted loss per share, in the first quarter of 2023. The decrease was primarily attributable to the aforementioned increases in gross profit and a year-over-year decrease in interest expense due to lower debt outstanding.

Adjusted EBITDA improved to \$(3.1) million compared to \$(3.7) million in the first quarter of 2023, primarily driven by the aforementioned cost optimization efforts. Adjusted EBITDA margin was (7.1)% compared to (6.8)% in the prior year period, with the decline primarily a result of the aforementioned lower net sales base.

#### **Segment Results**

Ascent Chemicals – net sales in the first quarter of 2024 were \$20.3 million compared to \$23.7 million in the first quarter of 2023. Operating loss in the first quarter was \$1.4 million compared to operating income of \$1.4 million in the prior year period. Adjusted EBITDA in the first quarter was \$(0.3) million compared to \$2.5 million in the prior year period. As a percentage of segment net sales, adjusted EBITDA was (1.4)% compared to 10.5% in the first quarter of 2023.

Ascent Tubular – net sales from continuing operations in the first quarter of 2024 were \$23.8 million compared to \$31.1 million in the first quarter of 2023. Operating loss from continuing operations in the first quarter decreased to \$1.5 million compared to operating loss from continuing operations of \$3.3 million in the prior year period. Adjusted EBITDA from continuing operations in the first quarter was \$(0.7) million compared to \$(2.4) million in the prior year period. As a percentage of segment net sales, adjusted EBITDA was \$(3.0)% compared to \$(7.7)% in the first quarter of 2023.

#### **Liquidity**

As of March 31, 2024, the Company had no debt outstanding under its revolving credit facilities and had \$63.6 million in availability under its revolving credit facility.

For the quarter ended March 31, 2024, the Company repurchased 16,330 shares at an average cost of \$9.97 per share for approximately \$0.2 million.

#### **Conference Call**

Ascent will conduct a conference call today at 5:00 p.m. Eastern time to discuss its results for the first quarter ended March 31, 2024.

Ascent management will host the conference call, followed by a question-and-answer period.

Date: Wednesday, May 8, 2024 Time: 5:00 p.m. Eastern time Live Call Registration Link: Here Webcast Registration Link: Here

To access the call by phone, please register via the live call registration link above or dere and you will be provided with dial-in instructions and details. If you have any difficulty connecting with the conference call, please contact Gateway Group at 1-949-574-3860.

The conference call will also be broadcast live and available for replayhere. The webcast will be archived for one year in the investor relations section of the Company's website at <a href="https://www.ascentco.com">www.ascentco.com</a>.

#### **About Ascent Industries Co.**

Ascent Industries Co. (Nasdaq: ACNT) is a company that engages in a number of diverse business activities including the production of specialty chemicals and industrial tubular products. For more information about Ascent, please visit its website at <a href="https://www.ascentco.com">www.ascentco.com</a>.

#### **Forward-Looking Statements**

This press release may include "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable federal securities laws. All statements that are not historical facts are forward-looking statements. Forward looking statements can be identified through the use of words such as "estimate," "project," "intend," "expect," "believe," "should," "anticipate," "hope," "optimistic," "plan," "outlook," "should," "could," "may" and similar expressions. The forward-looking statements are subject to certain risks and uncertainties which could cause actual results to differ materially from historical results or those anticipated. Readers are cautioned not to place undue reliance on these forward-looking statements and to review the risks as set forth in more detail in Ascent Industries Co.'s Securities and Exchange Commission filings, including our Annual Report on Form 10-K, which filings are available from the SEC or on our website. Ascent Industries Co. assumes no obligation to update any forward-looking information included in this release.

#### **Non-GAAP Financial Information**

Financial statement information included in this earnings release includes non-GAAP (Generally Accepted Accounting Principles) measures and should be read along with the accompanying tables which provide a reconciliation of non-GAAP measures to GAAP measures.

Adjusted EBITDA is a non-GAAP financial measure that the Company believes is useful to investors in evaluating its results to determine the value of a company. An item is excluded in the measure if its periodic value is inconsistent and sufficiently material that not identifying the item would render period comparability less meaningful to the reader or if including the item provides a clearer representation of normalized periodic earnings. The Company excludes in Adjusted EBITDA two categories of items: 1) Base EBITDA components, including: interest expense, income taxes, depreciation and amortization, and 2) Material transaction costs including: goodwill impairment, asset impairment, gain on lease modification, stock-based compensation, non-cash lease cost, acquisition costs and other fees, loss on extinguishment of debt, retention costs and restructuring & severance costs from net income.

Management believes that these non-GAAP measures are useful because they are key measures used by our management team to evaluate our operating performance, generate future operating plans and make strategic decisions as well as allow readers to compare the financial results between periods. Non-GAAP measures should not be considered as an alternative to any measure of performance or financial condition as promulgated under GAAP, and investors should consider the Company's performance and financial condition as reported under GAAP and all other relevant information when assessing the performance or financial condition of the Company. Non-GAAP measures have limitations as analytical tools, and investors should not consider them in isolation or as a substitute for analysis of the Company's results or financial condition as reported under GAAP.

# **Company Contact**

Ryan Kavalauskas Chief Financial Officer 1-630-884-9181

#### **Investor Relations**

Cody Slach and Cody Cree Gateway Group, Inc. 1-949-574-3860 ACNT@gateway-grp.com

		(Unaudited) March 31, 2024		December 31, 2023	
Assets	_				
Current assets:					
Cash and cash equivalents	\$	1,299	\$	1,851	
Accounts receivable, net of allowance for credit losses of \$792 and \$463, respectively		28,160		26,604	
Inventories		51,197		52,306	
Prepaid expenses and other current assets		4,146		4,879	
Assets held for sale		1,792		2,912	
Current assets of discontinued operations		46		861	
Total current assets		86,640		89,413	
Property, plant and equipment, net		28,648		29,755	
Right-of-use assets, operating leases, net		27,431		27,784	
Intangible assets, net		8,129		8,496	
Deferred income taxes		7,366		5,808	
Deferred charges, net		79		104	
Other non-current assets, net		2,678		1,935	
Total assets	\$	160,971	\$	163,295	
Liabilities and Chambaldow! Equity					
Liabilities and Shareholders' Equity Current liabilities:					
Accounts payable	\$	20,549	\$	16,416	
Accounts payable  Accrued expenses and other current liabilities	3	4,824	Ф	5,108	
Current portion of note payable		4,824		360	
Current portion of operating lease liabilities		1,170		1,140	
Current portion of finance lease liabilities		288		292	
Current liabilities of discontinued operations		1,376		1,473	
Total current liabilities		28,295		24.789	
Long-term portion of operating lease liabilities		29,419		29,729	
Long-term portion of operating lease habilities  Long-term portion of finance lease liabilities		1,236		1,307	
Other long-term liabilities		57		60	
Total non-current liabilities	<u></u>	30.712	-	31.096	
Total liabilities	\$	59.007	\$	55,885	
Commitments and contingencies	<del>9</del>	39,007	φ	33,863	
0					
Shareholders' equity:					
Common stock, par value \$1 per share; 24,000,000 shares authorized; 11,085,103 and 10,124,781 shares issued and outstanding, respectively	\$	11,085	\$	11,085	
Capital in excess of par value		47,097		47,333	
Retained earnings		53,024		58,517	
		111,206		116,935	
Less: cost of common stock in treasury - 960,323 and 990,282 shares, respectively		(9,242)		(9,525)	
Total shareholders' equity		101,964		107,410	
Total liabilities and shareholders' equity	\$	160,971	\$	163,295	

Note: The condensed consolidated balance sheets at December 31, 2023 have been derived from the audited consolidated financial statements at that date.

(\$ in thousands, except per share data)

		Three Months Ended March 31,	
		:4	2023
Net sales			
Tubular Products	\$	23,814 \$	
Specialty Chemicals		20,296	23,749
All Other			50
		44,110	54,860
Operating (loss) income from continuing operations			
Tubular Products		(1,502)	(3,293
Specialty Chemicals		(1,439)	1,352
All Other		(162)	(479
Corporate			
Unallocated corporate expenses		(2,150)	(3,704
Acquisition costs and other		_	(259
Total Corporate		(2,150)	(3,963
Operating loss		(5,253)	(6,383
Interest expense		127	1,10
Other, net		(120)	(95
Loss from continuing operations before income taxes		(5,260)	(7,395
Income tax benefit		(1,166)	(1,607
Loss from continuing operations	·	(4,094)	(5,788
(Loss) income from discontinued operations, net of tax		(1,399)	589
Net loss	\$	(5,493) \$	(5,199
Net loss per common share from continuing operations			
Basic	\$	(0.41) \$	(0.57
Diluted	\$	(0.41) \$	
Net (loss) income per common share from discontinued operations			
Basic	\$	(0.14) \$	
Diluted	\$	(0.14) \$	0.00
Net loss per common share			
Basic	\$	(0.54) \$	
Diluted	\$	(0.54) \$	(0.51
Average shares outstanding			
Basic		10,094	10,148
Diluted		10,094	10,148
Other data:			
Adjusted EBITDA <sup>1</sup>	\$	(3,115) \$	(3,735

<sup>1</sup>The term Adjusted EBITDA is a non-GAAP financial measure that the Company believes is useful to investors in evaluating its results to determine the value of a company. An item is excluded in the measure if its periodic value is inconsistent and sufficiently material that not identifying the item would render period comparability less meaningful to the reader or if including the item provides a clearer representation of normalized periodic earnings. The Company excludes in Adjusted EBITDA two categories of items: 1) Base EBITDA components, including: interest expense, income taxes, depreciation and amortization, and 2) Material transaction costs including: goodwill impairment, asset impairment, gain on lease modification, stock-based compensation, non-cash lease cost, acquisition costs and other fees, retention costs and restructuring & severance costs from net income. For a reconciliation of this non-GAAP measure to the most comparable GAAP equivalent, refer to the Reconciliation of Net Income (Loss) to Adjusted EBITDA.

	Three Mo	Three Months Ended March 31,		
	2024		2023	
Operating activities				
Net loss	\$	5,493) \$	(5,199)	
(Loss) income from discontinued operations, net of tax	(	1,399)	589	
Net loss from continuing operations		4,094)	(5,788)	
Adjustments to reconcile net loss to net cash provided by operating activities:				
Depreciation expense		1,522	1,549	
Amortization expense		367	376	
Amortization of debt issuance costs		25	25	
Deferred income taxes		1,166)	353	
Provision for (reduction of) losses on accounts receivable		330	(57)	
(Reduction of) provision for losses on inventories		(73)	791	
Loss on disposal of property, plant and equipment		_	182	
Non-cash lease expense		55	64	
Stock-based compensation expense		209	319	
Changes in operating assets and liabilities:				
Accounts receivable	(	1,885)	(1,072)	
Inventories		1,182	9,492	
Other assets and liabilities		(73)	297	
Accounts payable		4,022	6,827	
Accrued expenses		(283)	1,629	
Accrued income taxes		78	(2,577)	
Net cash provided by operating activities - continuing operations		216	12,410	
Net cash provided by operating activities - discontinued operations		47	980	
Net cash provided by operating activities		263	13,390	
Investing activities				
Purchases of property, plant and equipment		(305)	(586)	
Net cash used in investing activities - continuing operations		(305)	(586)	
Net cash used in investing activities - discontinued operations		_	(238)	
Net cash used in investing activities		(305)	(824)	
Financing activities		(===)	(== 1)	
Borrowings from long-term debt	4	0,950	67,488	
Payments on long-term debt		0,950)	(80,384)	
Payments on note payable	(e	(271)	(289)	
Principal payments on finance lease obligations		(76)	(74)	
Repurchase of common stock		(163)	(327)	
Net cash used in financing activities		(510)	(13,586)	
Decrease in cash and cash equivalents		(552)	(1,020)	
Less: Cash and cash equivalents of discontinued operations		(332)	(1,020)	
Cash and cash equivalents of discontinued operations  Cash and cash equivalents, beginning of period		1,851	1,440	
	<u> </u>			
Cash and cash equivalents, end of period	\$	1,299 \$	421	

(\$ in thousands)  Consolidated  Net loss from continuing operations  Adjustments: Interest expense Income taxes Depreciation Amortization  EBITDA  Acquisition costs and other Stock-based compensation Non-cash lease expense Retention expense Retention expense Restructuring and severance costs  Adjusted EBITDA  % sales  Specialty Chemicals  Net (loss) income  Adjustments: Interest expense	\$	2024	2023
Net loss from continuing operations  Adjustments: Interest expense Income taxes Depreciation Amortization  EBITDA Acquisition costs and other Stock-based compensation Non-cash lease expense Retention expense Restructuring and severance costs  Adjusted EBITDA % sales  Specialty Chemicals Net (loss) income  Adjustments: Interest expense	\$	(4.004)	
Adjustments: Interest expense Income taxes Depreciation Amortization EBITDA Acquisition costs and other Stock-based compensation Non-cash lease expense Retention expense Restructuring and severance costs Adjusted EBITDA % sales  Specialty Chemicals Net (loss) income Adjustments: Interest expense	\$	(4.004)	
Interest expense Income taxes Depreciation Amortization EBITDA Acquisition costs and other Stock-based compensation Non-cash lease expense Retention expense Restructuring and severance costs Adjusted EBITDA % sales  Specialty Chemicals Net (loss) income Adjustments: Interest expense		(4,094) \$	(5,788)
Income taxes Depreciation Amortization EBITDA Acquisition costs and other Stock-based compensation Non-cash lease expense Retention expense Retention expense Restructuring and severance costs Adjusted EBITDA % sales  Specialty Chemicals Net (loss) income Adjustments: Interest expense			
Depreciation Amortization  EBITDA  Acquisition costs and other Stock-based compensation Non-cash lease expense Retention expense Restructuring and severance costs  Adjusted EBITDA  % sales  Specialty Chemicals Net (loss) income  Adjustments: Interest expense		127	1,106
Amortization  EBITDA  Acquisition costs and other Stock-based compensation  Non-cash lease expense Retention expense Restructuring and severance costs  Adjusted EBITDA  % sales  Specialty Chemicals Net (loss) income  Adjustments: Interest expense		(1,166)	(1,607)
EBITDA  Acquisition costs and other Stock-based compensation Non-cash lease expense Retention expense Restructuring and severance costs  Adjusted EBITDA % sales  Specialty Chemicals Net (loss) income  Adjustments: Interest expense		1,522	1,549
Acquisition costs and other Stock-based compensation Non-cash lease expense Retention expense Restructuring and severance costs Adjusted EBITDA % sales  Specialty Chemicals Net (loss) income Adjustments: Interest expense		367	376
Stock-based compensation Non-cash lease expense Retention expense Restructuring and severance costs Adjusted EBITDA % sales  Specialty Chemicals Net (loss) income Adjustments: Interest expense	·	(3,244)	(4,364)
Non-cash lease expense Retention expense Restructuring and severance costs  Adjusted EBITDA % sales  Specialty Chemicals Net (loss) income Adjustments: Interest expense		12	261
Retention expense Restructuring and severance costs  Adjusted EBITDA % sales  Specialty Chemicals Net (loss) income Adjustments: Interest expense		59	220
Restructuring and severance costs  Adjusted EBITDA % sales  Specialty Chemicals Net (loss) income Adjustments: Interest expense		55	64
Adjusted EBITDA % sales  Specialty Chemicals Net (loss) income Adjustments: Interest expense		3	_
% sales  Specialty Chemicals  Net (loss) income  Adjustments: Interest expense		_	84
Specialty Chemicals Net (loss) income Adjustments: Interest expense	\$	(3,115) \$	(3,735)
Net (loss) income Adjustments: Interest expense		(7.1)%	(6.8)%
Adjustments: Interest expense			
Interest expense	\$	(1,458) \$	1,342
Demociation amount		19	12
Depreciation expense		954	952
Amortization expense		169	158
EBITDA		(316)	2,464
Acquisition costs and other		_	2
Stock-based compensation		7	8
Non-cash lease expense		19	24
Specialty Chemicals Adjusted EBITDA	\$	(290) \$	2,498
% segment sales		(1.4)%	10.5 %
Tubular Products			
Net loss from continuing operations	\$	(1,502) \$	(3,293)
Adjustments:	Ψ 	(1,5 02) ψ	(5,275)
Depreciation expense		544	575
Amortization expense		198	218
EBITDA		(760)	(2,500)
Acquisition costs and other		12	(2,500)
Stock-based compensation		11	(20)
Non-cash lease expense		25	31
Restructuring and severance costs			84
Tubular Products Adjusted EBITDA			٠.
% segment sales	\$	(712) \$	(2,405)